The BIOSOLVE II trial: a step forward for the bioresorbable scaffold?

被引：2
作者：
Faxon, David P. [1 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA 02108 USA
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷 / 35期
关键词：
CORONARY-ARTERY-DISEASE; ABSORBABLE METAL SCAFFOLD; CLINICAL-OUTCOMES; VASCULAR SCAFFOLDS; MULTICENTER; LESIONS; IMPLANTATION; SYSTEM; STENTS; METAANALYSIS;
D O I：
10.1093/eurheartj/ehw227
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：2710 / 2712
页数：3
相关论文
共 21 条
  • [1] Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions
    Abizaid, Alexandre
    Costa, Ricardo A.
    Schofer, Joachim
    Ormiston, John
    Maeng, Michael
    Witzenbichler, Bernhard
    Botelho, Roberto V.
    Ribamar Costa, J., Jr.
    Chamie, Daniel
    Abizaid, Andrea S.
    Castro, Juliana P.
    Morrison, Lynn
    Toyloy, Sara
    Bhat, Vinayak
    Yan, John
    Verheye, Stefan
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (06) : 565 - 574
  • [2] The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled
    Abizaid, Alexandre
    Ribamar Costa, J., Jr.
    Bartorelli, Antonio L.
    Whitbourn, Robert
    van Geuns, Robert Jan
    Chevalier, Bernard
    Patel, Tejas
    Seth, Ashok
    Stuteville, Marrianne
    Dorange, Cecile
    Cheong, Wai-Fung
    Sudhir, Krishnankutty
    Serruys, Patrick W.
    [J]. EUROINTERVENTION, 2015, 10 (12) : 1396 - 1401
  • [3] Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease
    Campos, Carlos M.
    Muramatsu, Takashi
    Iqbal, Javaid
    Zhang, Ya-Jun
    Onuma, Yoshinobu
    Garcia-Garcia, Hector M.
    Haude, Michael
    Lemos, Pedro A.
    Warnack, Boris
    Serruys, Patrick W.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (12) : 24492 - 24500
  • [4] Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials
    Cassese, Salvatore
    Byrne, Robert A.
    Ndrepepa, Gjin
    Kufner, Sebastian
    Wiebe, Jens
    Repp, Janika
    Schunkert, Heribert
    Fusaro, Massimiliano
    Kimura, Takeshi
    Kastrati, Adnan
    [J]. LANCET, 2016, 387 (10018) : 537 - 544
  • [5] Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial
    Diletti, Roberto
    Farooq, Vasim
    Girasis, Chrysafios
    Bourantas, Christos
    Onuma, Yoshinobu
    Heo, Jung Ho
    Gogas, Bill D.
    van Geuns, Robert-Jan
    Regar, Evelyn
    de Bruyne, Bernard
    Dudek, Dariusz
    Thuesen, Leif
    Chevalier, Bernard
    McClean, Dougal
    Windecker, Stephan
    Whitbourn, Robert J.
    Smits, Pieter
    Koolen, Jacques
    Meredith, Ian
    Li, Xiaolin
    Miquel-Hebert, Karine
    Veldhof, Susan
    Garcia-Garcia, Hector M.
    Ormiston, John A.
    Serruys, Patrick W.
    [J]. HEART, 2013, 99 (02) : 98 - 105
  • [6] Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
    Ellis, Stephen G.
    Kereiakes, Dean J.
    Metzger, D. Christopher
    Caputo, Ronald P.
    Rizik, David G.
    Teirstein, Paul S.
    Litt, Marc R.
    Kini, Annapoorna
    Kabour, Ameer
    Marx, Steven O.
    Popma, Jeffrey J.
    McGreevy, Robert
    Zhang, Zhen
    Simonton, Charles
    Stone, Gregg W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (20) : 1905 - 1915
  • [7] Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents:: a prospective, non-randomised multicentre trial
    Erbel, Raimund
    Di Mario, Carlo
    Bartunek, Jozef
    Bonnier, Johann
    de Bruyne, Bernard
    Eberli, Franz R.
    Erne, Paul
    Haude, Michael
    Heublein, Bernd
    Horrigan, Mark
    Ilsley, Charles
    Boese, Dirk
    Koolen, Jacques
    Luescher, Thomas F.
    Weissman, Neil
    Waksman, Ron
    [J]. LANCET, 2007, 369 (9576) : 1869 - 1875
  • [8] Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial
    Haude, Michael
    Ince, Huseyin
    Abizaid, Alexandre
    Toelg, Ralph
    Lemos, Pedro Alves
    von Birgelen, Clemens
    Christiansen, Evald Hoj
    Wijns, William
    Neumann, Franz-Josef
    Kaiser, Christoph
    Eeckhout, Eric
    Lim, Soo Teik
    Escaned, Javier
    Onuma, Yoshinobu
    Garcia-Garcia, Hector M.
    Waksman, Ron
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (35) : 2701 - 2709
  • [9] Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial
    Haude, Michael
    Ince, Hueseyin
    Abizaid, Alexandre
    Toelg, Ralph
    Lemos, Pedro Alves
    von Birgelen, Clemens
    Christiansen, Evald Hoj
    Wijns, William
    Neumann, Franz-Josef
    Kaiser, Christoph
    Eeckhout, Eric
    Teik Lim, Soo
    Escaned, Javier
    Garcia-Garcia, Hector M.
    Waksman, Ron
    [J]. LANCET, 2016, 387 (10013) : 31 - 39
  • [10] Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial
    Haude, Michael
    Erbel, Raimund
    Erne, Paul
    Verheye, Stefan
    Degen, Hubertus
    Boese, Dirk
    Vermeersch, Paul
    Wijnbergen, Inge
    Weissman, Neil
    Prati, Francesco
    Waksman, Ron
    Koolen, Jacques
    [J]. LANCET, 2013, 381 (9869) : 836 - 844
123